On 22nd-23rd August 2022 Universität Zurich are hosting a conference: Drugs and the ‘Industrial Situation’ 1800s-1960s. Find out more about the conference and its program below.
Editor’s note: Maeleigh Tidd returns with another contribution to the Pharmaceutical Inequalities feature, this time co-authored with a graduate student colleague, Lucy Abrams. Mae and Lucy discuss the history of LGBTQ+ health in the USA, and situate existing LGBTQ+ rights within the international context. They subsequently discuss how pharmacists play a key role in providing gender-affirming care, and how this can be improved upon. The Pharmaceutical Inequalities series is funded by the Holtz Center and the Evjue Foundation.
Editor’s Note: This is an edited version of Paul Gootenberg’s Presidential Address at the Alcohol and Drugs History Society 2022 Conference, delivered at Universidad Nacional Autónima de México (UNAM) on 15 June 2022.
Thank you/mil gracias for the kind introductions and especially to UNAM and and its renowned Instituto de Investigaciones Sociales for hosting and welcoming us to our international biennial ADHS conference.
It is a deep privilege to deliver this ADHS Presidential Address, particularly here at UNAM, the intellectual heart of Mexico, and even of “las Américas”
So, why are we here in Mexico?
The easy answers, being a beautiful, peopled, world cosmopolis, wonderful food and tequila, and everyday links with drug wars, need not be addressed!
Of course, we’re here mainly for the serious biennial purpose of intellectual exchanges — through new papers, roundtables, and exciting keynotes — around our booming, increasingly recognized field of global drug and alcohol history.
Editor’s Note: Anny Ortiz returns with a third contribution to our Pharmaceutical Inequalities series with reflections on her recent trip to the Medical Psychedelic House of Davos to co-present alongside her colleagues from the Indigenous Medicine Conservation Fund and launch their ‘Grow Medicine’ project. The Pharmaceutical Inequalities series is funded by the Holtz Center and the Evjue Foundation.
I recently returned from a 10-day trip to Switzerland and Canada. I was in Toronto, Canada at a conference called “From Research to Reality” co-presenting a poster titled “5-MeO-DMT: Synthesis and therapeutic potential for treating psychological disorders”. It was surprising to see that there were two separate presentations by personnel from the US Food and Drug Administration (FDA), one of which was titled “Challenges in Conducting Clinical Research with Schedule I Psychedelics: From the 1960s to the Present”, presented by Dr. Katherine Bonson, and the other titled “World Regulatory and Policy Discussion: A Pathway Forward”, presented by Javier Muniz. If FDA staff presenting at a psychedelic science conference is not a sign of the times, I don’t know what is.
Immediately preceding the Toronto conference, I was in Davos, Switzerland, as part of the Indigenous Medicine Conservation Fund (IMCF), which was a sponsor of a landmark event titled “Medical Psychedelic House of Davos” (no connection to the World Economic Forum, usually hosted in Davos). I would like to share some highlights of what transpired there.
I was recently reading Dr Jessica Taylor’s latest book Sexy but Psycho: How the Patriarchy Uses Women’s Trauma Against Them. Taylor is a working class, radical, lesbian feminist who has a proven track-record working with traumatised women and girls. In this book she argues for a trauma-informed approach to working with women and girls and documents the long-standing tendency by the patriarchy (systems that uphold male power) to pathologise them as a result of their traumas, reframe them as mental illness, and unnecessarily medicate them for these ‘disorders’.
Pre-existing research shows that women are more likely to be diagnosed with depression, anxiety and somatic disorders, borderline personality disorder, panic disorder, phobias, suicide ideation and attempts, postpartum depression and psychosis, eating disorders and PTSD (Riecher-Rossler, 2016). Furthermore, women are more likely to be diagnosed with multiple psychiatric disorders at one time (Anxiety and Depression Association of America, 2019).
Editor’s Note: Amanda Pratt’s first contribution to our Pharmaceutical Inequalities series offers this insightful interview with Vincent Wartenweiler PharmD, an independent community pharmacist and Master’s student in Psychoactive Pharmaceutical Investigation at UW-Madison. Amanda (AP) and Vincent (VW) sat down on March 24, 2022 to discuss a qualitative project Vincent published in 2021 to determine perceptions of pharmacy stakeholders around opioid use disorder vaccines. In addition to providing a glimpse into a significant milestone for the history of alcohol, drugs and pharmacy–the development of substance use disorder vaccines–this interview sheds light on potential methodologies for understanding vaccine hesitancy. The Pharmaceutical Inequalities series is funded by the Holtz Center and the Evjue Foundation.
Festival Season is upon us, and the Health Service Executive (HSE) in Ireland recently launched a new drug campaign targeted at festival-goers. The design and imagery of the Reduce the Harms at Festivals campaign takes a playful approach. Borrowing heavily from 1970s animation, the campaign features images of anthropomorphized objects and colourful cartoons; a smiling first aid kit high-fives a heart in platform shoes patched up with a plaster (‘Medics are your Mates’); a snail in festival style staples – bum bag and bucket hat (‘Start Low and Go Slow’).
Editor’s Note: In her latest post for Points Kawal Deep Kour resurrects a past editorial feature: ‘Cannabis: Global Histories‘. She contributes to this rich history by outlining the multitudinous roles and affordances of cannabis within Indian cultures.
Much before the Irish physician Sir William Brooke O Shaughnessy (1808-1889) introduced cannabis into Western medicine sometime around the mid-nineteenth century, Ganja (hemp) had already been part of India’s living culture as medicine and an intoxicating agent – even before 1000 B.C. The use of hemp in India was also mentioned by Jewish physician Garcia de Orta in 1563 and subsequently by the Dutch administrator in India, Hendrik van Rheede ( 1636-1691) who in his treatise, Hortus Malabaricus (the garden of Malabar) described that ganja smoking was popular on the Malabar coast. Ganja is an intoxicating drug, derived from the leaves of the Cannabis Indica plant. The philosophy of cannabis consumption in India entails the sacred lore of having emerged in the form of a pot of nectar while the gods and the demons were churning the ocean with the help of mountain Mandara and Vasuki, the serpent king. It was named Vijaya and was believed to bestow victory upon its votaries. It is said that the Gods then wished that it be sent to live with humans on Earth and aid in their merriment and enjoyment of the pleasures of life.